|Mr. Peter David Rands||CEO & Founder||135.64k||N/A||N/A|
|Mr. David Steel||Chief Financial Officer||20.12k||N/A||N/A|
|Ms. Marie Claire Layzell||COO & Head of CMC||128.47k||N/A||N/A|
|Dr. Carol Routledge||Chief Scientific & Medical Officer||128.47k||N/A||N/A|
|Mr. George Tziras||Chief Bus. Officer||51.62k||N/A||N/A|
|Ms. Nina Kumari M.D.||Head of Bus. Devel.||N/A||N/A||N/A|
|Ms. Ellen James Ph.D.||Head of R&D||N/A||N/A||N/A|
|Mr. Richard M. Kimel||Corp. Sec.||N/A||N/A||1967|
|Mr. Jim Rennie||Director of Devel. and Member of Scientific & Advisory Board||N/A||N/A||N/A|
Small Pharma Inc., a clinical stage neuropharmaceutical company, engages in the IP-led development of novel treatments for depression and other mental health conditions. The company's lead product candidate is SPL026, a N,N-dimethyltryptamine (DMT) assisted therapy that is in Phase I/IIa randomized controlled clinical trial for the treatment of major depressive disorders. Its preclinical product candidates include SPL028 and SPL029 tryptamine analogues to assess and deliver alternative treatment profiles for the treatment of depression and other mental health disorders; and SPL801, an oral formulation of 6 -hydroxynorketamine. The company was founded in 2015 and is headquartered in London, United Kingdom.
Small Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.